跳至主要内容
临床试验/NCT03977831
NCT03977831已完成不适用

A Controlled Blinded Randomized Feasibility Study of Open Radical Cystectomy (ORC) Versus Robot-Assisted Radical Cystectomy With Intracorporal Urinary Diversion (iRARC) Under an Enhanced Recovery After Surgery (ERAS) Setup

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年6月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Participants blinded at discharge

研究概览

简要总结

The purpose of the study to compare two established methods of radical cystectomy (RC) in patients with bladder cancer. The participants will be treated under conditions in alignment with up-to-date guidelines and care. We wish to investigate whether it is feasible to compare the two methods under conditions of the highest methodological quality.

详细描述

Radical cystectomy (RC) is a comprehensive surgery including pelvic lymph node dissection and urinary diversion. The surgery is originally performed as an open procedure (ORC) but with advances in technology the procedure is now also offered as a robot-assisted laparoscopic procedure (RARC). It remains questionable if RARC is superior to ORC in terms of surgical outcomes.

Several studies have described outcomes following RARC of which most are comparative studies with only five studies being randomized controlled trials (RCTs). Overall, significant differences in operating room time, estimated blood loss, time to flatus and bowel movement as well as use of morphine sulfate equivalents in favor of RARC has been demonstrated with the exception of operating room time. However, no studies have demonstrated a significant reduction in risk of 30- or 90-day complication rates between ORC and RARC. The RCTs have not been blinded, and therefore may be subject to bias in terms of expectations from patients and care providers. Also, in the already conducted RCTs of ORC versus RARC the urinary diversion has been done extracorporally. Today, it is possible to conduct the whole procedure of RARC intracorporally (iRARC), potentially reducing the surgical stress further. Lastly, the previously conducted RCTs have not consequently been managed under an Enhanced Recovery After Surgery (ERAS) setup. Currently, a multicenter study comparing ORC with RARC is recruiting in the United Kingdom in which the patients are treated with iRARC and under an ERAS setup. The present study will compare the two methods blinded for the participants and all health care providers involved in the postoperative care from the time the patient exits the operating room (OR). Blinded studies in surgery are rare but in gastrointestinal surgery, a blinded study of open versus laparoscopic colonic resection has demonstrated to be feasible and thus we believe that such study must be feasible in an RC setting.

Participants will be randomized 1:1 to either ORC or RARC. Blinding: The study is blinded for the patient and for the group of nurses and doctors that will be responsible for the postoperative care. The postoperative care will be managed by members of the bladder cancer team other than the operating surgeon, and OR staff will not be involved in the postoperative care. The abdominal wound will be bandaged to hide the wounds from both an open and laparoscopic procedure. The blinding will be maintained until discharge from hospital.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • non-metastatic disease
  • fit for both ORC and RARC
  • Patient-selected urinary diversion: ileal conduit

排除标准

  • if not able to speak/understand Danish
  • not able to cooperate for fully informed consent
  • need for extensive concomitant surgery (i.e. nephroureterectomy)
  • prior down staging chemotherapy (prior neoadjuvant chemotherapy accepted)
  • prior radiation therapy
  • prior major extensive abdominal or pelvic surgery
  • prior peritonitis
  • conditions contraindicating extended Trendelenburg's position

结局指标

主要结局

Participants blinded at discharge

时间窗: 12 months

Number of patients that was not unblinded at discharge

次要结局

  • Use of opioids(until diacharge or up to 90 days, whichever comes first)
  • Days Alive and Out of Hospital (DAOH)(90 days from surgery)
  • 90-day complication rate(90 days after surgery)
  • Readmission rate(90 days after surgery)
  • Quality of Life (QoL): EORTC QLQ-BLM30(90 days after surgery)
  • Length of Stay (LOS)(12 months)
  • Quality of Life (QoL): EORTC QLQ-C30(90 days after surgery)
  • 30-day complication rate(30 days after surgery)
  • Blood loss(4 days after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ulla Nordström Joensen

Associate Professor, PhD

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验